Alnylam Pharmaceuticals Inc has a consensus price target of $194.79, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from BMO Capital, HC Wainwright & Co., and Cantor Fitzgerald on March 27, 2024, March 5, 2024, and February 23, 2024. With an average price target of $259.67 between BMO Capital, HC Wainwright & Co., and Cantor Fitzgerald, there's an implied 68.19% upside for Alnylam Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/27/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 51.56% | BMO Capital | Kostas Biliouris | $234 → $234 | Maintains | Outperform | Get Alert |
03/05/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 155.85% | HC Wainwright & Co. | Patrick Trucchio | → $395 | Reiterates | Buy → Buy | Get Alert |
02/23/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | -2.84% | Cantor Fitzgerald | Olivia Brayer | $165 → $150 | Maintains | Neutral | Get Alert |
02/21/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 52.21% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
02/20/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 6.87% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
02/20/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 52.21% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
02/16/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 4.28% | Wells Fargo | Tiago Fauth | $171 → $161 | Maintains | Equal-Weight | Get Alert |
02/16/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 47.03% | Citigroup | David Lebovitz | $237 → $227 | Maintains | Buy | Get Alert |
02/16/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 52.21% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
02/16/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 45.73% | Chardan Capital | Keay Nakae | $250 → $225 | Maintains | Buy | Get Alert |
02/16/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 12.05% | Goldman Sachs | Salveen Richter | $230 → $173 | Downgrade | Buy → Neutral | Get Alert |
02/15/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 29.54% | Needham | Joseph Stringer | → $200 | Reiterates | Buy → Buy | Get Alert |
02/15/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 6.87% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
02/15/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | — | Wolfe Research | Andy Chen | — | Initiates | → Peer Perform | Get Alert |
02/14/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 52.21% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
02/13/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 14% | Morgan Stanley | Michael Ulz | $184 → $176 | Maintains | Equal-Weight | Get Alert |
02/12/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 6.87% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
02/01/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 10.11% | JP Morgan | Jessica Fung | $150 → $170 | Maintains | Neutral | Get Alert |
01/22/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $154.39 | 6.87% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
The latest price target for Alnylam Pharmaceuticals (NASDAQ: ALNY) was reported by BMO Capital on March 27, 2024. The analyst firm set a price target for $234.00 expecting ALNY to rise to within 12 months (a possible 53.33% upside). 65 analyst firms have reported ratings in the last year.
The latest analyst rating for Alnylam Pharmaceuticals (NASDAQ: ALNY) was provided by BMO Capital, and Alnylam Pharmaceuticals maintained their outperform rating.
The last upgrade for Alnylam Pharmaceuticals Inc happened on May 5, 2023 when BMO Capital raised their price target to $250. BMO Capital previously had a market perform for Alnylam Pharmaceuticals Inc.
The last downgrade for Alnylam Pharmaceuticals Inc happened on February 16, 2024 when Goldman Sachs changed their price target from $230 to $173 for Alnylam Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alnylam Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alnylam Pharmaceuticals was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.
While ratings are subjective and will change, the latest Alnylam Pharmaceuticals (ALNY) rating was a maintained with a price target of $234.00 to $234.00. The current price Alnylam Pharmaceuticals (ALNY) is trading at is $152.62, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.